{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-187977","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2022-07-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.322085+00:00","generated_at":"2026-06-24T21:26:39.659264+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adagio names David Hering permanent CEO with $600K salary, 2M share option; board overhauled","bullets":["David Hering, previously interim CEO and COO, appointed permanent CEO and director effective July 5, 2022.","Hering receives $600K base salary, 60% target bonus, and initial option grant for 2,000,000 shares vesting over 48 months.","Eligible for additional option grant of up to 1,000,000 shares if performance goals achieved by Dec 31, 2022.","Annual meeting elects Tamsin Berry, Marc Elia, Clive Meanwell to board; Marc Elia appointed board chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-187977","json":"https://secwatch.observer/filing/0001193125-22-187977.json","markdown":"https://secwatch.observer/filing/0001193125-22-187977.md","text":"https://secwatch.observer/filing/0001193125-22-187977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522187977/0001193125-22-187977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522187977/d304609d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:26:39.659264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29dfe276b0","claim":"David Hering was appointed as Chief Executive Officer and Director at Invivyd, Inc..","evidence_excerpt":"On July 5, 2022 (the “Effective Date”), the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed David Hering, M.B.A., age 47, as the Company’s Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522187977/0001193125-22-187977-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}